b'HonorHealth Research and Innovation Institute is increasingly a destination and beacon of hope for those Innovative Grand Slam Clinical Trialfacing rare cancers. Advances Posts a Win in the Fight Againstagainst them cannot be made until someone makes Pancreatic Cancer them a priority. Powered by generosity, we are Stage IV pancreatic cancer. The diagnosis is terrifying for its transforming and saving the one percent survival rate. lives of patients who typically When Marybeth learned of her pancreatic cancer in Augusthave had littleif anyhope.2020, she turned to HRI 2in search of hope. An innovative Grand Slam clinical trial was showing promise, shrinkingMICHAEL S. GORDON, MD tumors substantially in 84 percent of patients in the study. Chief Medical Officer, HRI2After meeting with the HRI 2expert team, she qualified for the trial and began the grand slam: a regimen of five drugs, including three chemotherapy agents, a drug to help the immune system attack cancer cells and a form of vitamin D. After six months, Marybeth had responded so well she was placed on a maintenance program in early 2021. HonorHealth Research Institute saved my life, says Marybeth gratefully. Pancreatic cancer is a terrible and gloomy diagnosis. But HRI 2gave me hope when other medical institutions didnt. Their team supported me in so many waysphysically and emotionallyand its meant more to me than I can say.Today, Marybeth is busy swimming five to six miles weeklyand planning her wedding. In the not too distant past,I wouldnt have been here to do any of that, she says. Thanks to donor support of the Cellular Therapy Research Program, thank you HRI 2initiated a CAR-T multiple myeloma trial resulting in the near-term approval of an agent in this rare hematologic disorder, as well as opening the door for several new multiple myeloma-based cellular trials. This has made HRI 2a leading destination for those fighting rare and refractory cancers.HonorHealth Foundation 11'